Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers
Andrew R. Haas(University of Pennsylvania), János L. Tanyi(University of Pennsylvania), Mark H. O’Hara(University of Pennsylvania), Whitney L. Gladney(University of Pennsylvania), Simon F. Lacey(University of Pennsylvania), Drew A. Torigian(University of Pennsylvania), Michael C. Soulen(University of Pennsylvania), Lifeng Tian(University of Pennsylvania), Maureen McGarvey(University of Pennsylvania), Anne Marie Nelson(University of Pennsylvania), Caitlin S. Farabaugh(Cancer Research Center), Edmund K. Moon(University of Pennsylvania), Bruce L. Levine(University of Pennsylvania), J. Joseph Melenhorst(University of Pennsylvania), Gabriela Plesa(University of Pennsylvania), Carl H. June(University of Pennsylvania), Steven Μ. Albelda(University of Pennsylvania), Gregory L. Beatty(University of Pennsylvania)
Cited by 369Open Access
Abstract
CART-meso without cyclophosphamide. The best overall response was stable disease (11/15 patients). CART-meso cells expanded in the blood and reached peak levels by days 6-14 but persisted transiently. Cyclophosphamide pre-treatment enhanced CART-meso expansion but did not improve persistence beyond 28 days. CART-meso DNA was detected in 7/10 tumor biopsies. Human anti-chimeric antibodies (HACA) were detected in the blood of 8/14 patients. CART-meso cells were well tolerated and expanded in the blood of all patients but showed limited clinical activity. Studies evaluating a fully human anti-mesothelin CAR are ongoing.
Related Papers
No related papers found
Powered by citation graph analysis